Taysha Gene Therapies (TSHA) AI Stock Analysis

• Market Cap: $1.33B
• Dividend Yield: N/A
• Average Volume (3M): 3.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.71
• Revenue Growth: -36.36%
• EPS Growth: -945.72%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 273,919,370
• 10 Day Avg. Volume: 2,173,912
• 30 Day Avg. Volume: 3,073,819
• PEG Ratio: 0.08
• Price to Book (P/B): 6.05
• Price to Sales (P/S): 51.93
• P/FCF Ratio: -5.30
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 146.92
• Enterprise Value/Gross Profit: 153.89
• Enterprise Value/Ebitda: -9.39
• 1Y Price Target: $11.60
• Price Target Upside: 138.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -0.45
• Revenue Forecast (FY): $4.28M

• Rating: 53 Neutral
• Price Target: $5.00 ▲(2.88% Upside)

The score is held back primarily by weak financial performance (deep losses and persistent cash burn) and limited valuation support (negative P/E). These are partially offset by strong earnings-call catalysts around TSHA-102 (Breakthrough Therapy designation, pivotal-trial alignment, and stated cash runway), while technicals are mixed with softer near-term momentum.

Positive Factors

Regulatory De‑risking: Breakthrough Therapy

Breakthrough Therapy status materially raises the probability of accelerated regulatory review and approval for TSHA-102. This designation supports faster development timelines, strengthens partnership appeal, and reduces program execution risk, improving long‑term odds of commercial success.

Strategic Control: Regained Global Rights

Full ownership of TSHA-102 restores strategic and commercial flexibility, enabling Taysha to capture downstream economics, set global development strategy, and negotiate partnerships from a stronger position. That control supports durable value capture if the program advances.

Improved Capital Runway

A multi‑year cash runway into 2028 materially reduces near‑term financing pressure, allowing Taysha to complete pivotal trials and regulatory interactions without immediate dilutive raises. This funding stability enhances the firm’s ability to achieve value‑creating clinical inflection points.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow requires ongoing external financing to fund development. Over months to years this raises dilution risk, constrains strategic optionality, and forces prioritization of programs, making long‑term execution dependent on capital markets and partnerships.

No Commercial Revenue; Falling Top Line

As a clinical‑stage biotech without product sales and shrinking revenue, Taysha lacks recurring non‑dilutive income. This structural revenue gap prolongs dependence on financing and heightens exposure to trial outcomes, delaying sustainable profitability and commercial scale.

Rising R&D Spend and Larger Losses

Higher R&D and growing quarterly losses reflect necessary investment in manufacturing and trials but widen near‑term deficits. Persistently elevated spend without revenue amplifies financing needs and may force tradeoffs across programs, affecting long‑term pipeline breadth and timing.

Taysha Gene Therapies Business Overview & Revenue Model

Company Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

How the Company Makes Money

Taysha Gene Therapies primarily generates revenue through a combination of product sales, partnerships, and collaborations in the biotechnology sector. The company is focused on advancing its gene therapy candidates through clinical trials and subsequently commercializing these products upon regulatory approval. Key revenue streams include milestone payments from partnerships with larger pharmaceutical companies that may involve co-development or licensing of Taysha's gene therapies. Additionally, Taysha may receive royalties on sales of approved therapies, further contributing to its earnings. The company also benefits from grants and funding aimed at supporting research and development in gene therapies, which can provide crucial financial backing as it progresses through various stages of product development.

Taysha Gene Therapies Financial Statement Overview

Summary

Taysha Gene Therapies faces significant profitability and cash flow challenges typical of early-stage biotech firms. Despite improvements in leverage and revenue growth, negative net profit margins and cash flows highlight ongoing operational difficulties.

Income Statement

Taysha Gene Therapies has shown some revenue growth in the TTM period, but the company continues to operate at a significant loss with negative net profit margins. The gross profit margin is high, indicating efficient cost management relative to revenue, but the negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio has improved significantly in the TTM period, indicating better leverage management. However, the return on equity remains negative, reflecting ongoing profitability challenges. The equity ratio is stable, suggesting a reasonable balance between debt and equity.

Cash Flow

Cash flow metrics indicate a challenging environment with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow generation is aligned with net losses. However, the negative free cash flow growth rate in the TTM period is a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.31M	8.33M	15.45M	2.50M	0.00	0.00
Gross Profit	6.02M	8.33M	15.45M	15.00K	0.00	-9.00K
EBITDA	-98.71M	-87.95M	-105.20M	-159.73M	-172.60M	-59.97M
Net Income	-99.93M	-89.30M	-111.57M	-166.01M	-174.52M	-43.00M
Balance Sheet
Total Assets	316.55M	160.36M	172.73M	126.28M	213.96M	258.88M
Cash, Cash Equivalents and Short-Term Investments	297.34M	139.04M	143.94M	87.88M	149.10M	251.25M
Total Debt	69.08M	63.18M	61.11M	59.93M	63.09M	0.00
Total Liabilities	97.56M	88.84M	97.79M	125.33M	118.57M	7.58M
Stockholders Equity	218.99M	71.53M	74.94M	949.00K	95.38M	251.30M
Cash Flow
Free Cash Flow	-85.16M	-81.60M	-80.39M	-113.26M	-138.60M	-39.81M
Operating Cash Flow	-84.68M	-81.22M	-73.02M	-88.39M	-117.04M	-30.73M
Investing Cash Flow	-344.00K	-363.00K	-7.35M	-24.93M	-21.55M	-9.08M
Financing Cash Flow	224.68M	76.68M	136.39M	52.10M	39.08M	291.06M

Taysha Gene Therapies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Neutral. The current price of 4.86 is below the 20-day moving average (MA) of 5.43, below the 50-day MA of 4.90, and above the 200-day MA of 3.35, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 24.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSHA.

Taysha Gene Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMNM	58 Neutral	$2.27B	-6.81	-93.04%	―	-4.44%	63.58%
SPRY	54 Neutral	$1.12B	-13.96	-45.92%	―	5459.66%	-59.70%
TSHA	53 Neutral	$1.33B	-13.82	-64.93%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SANA	51 Neutral	$1.22B	-4.84	-96.11%	―	―	31.16%
RLAY	50 Neutral	$1.35B	-4.54	-41.14%	―	-16.50%	33.02%
PRME	50 Neutral	$772.59M	-2.82	-112.34%	―	647.13%	26.79%

Taysha Gene Therapies Corporate Events

Taysha Gene Therapies Amends Sales Agreement, Expands Offering

On November 4, 2025, Taysha Gene Therapies announced amendments to its Sales Agreement, increasing the aggregate offering amount to $212 million, and terminating its agreement with Leerink Partners LLC. The company also reported significant progress in its TSHA-102 program for Rett syndrome, including receiving FDA Breakthrough Therapy designation and finalizing pivotal trial protocols, positioning it to expedite its Biologics License Application submission. Taysha regained full rights to the TSHA-102 program, enhancing its strategic flexibility, and appointed David McNinch as Chief Commercial Officer to strengthen its commercial leadership.

The most recent analyst rating on (TSHA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Taysha Regains Full Rights to TSHA-102 Program

On October 16, 2025, Taysha Gene Therapies announced it has regained full rights to its lead TSHA-102 program for Rett syndrome after the expiration of a 2022 Option Agreement with Astellas. This development allows Taysha strategic flexibility to advance the program, which has shown promising safety and efficacy data, received FDA Breakthrough Therapy designation, and is poised for a pivotal trial this quarter, highlighting a significant market opportunity given the unmet medical need in Rett syndrome.

The most recent analyst rating on (TSHA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.